BOSTON, Jan. 9 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global bio/pharmaceutical services organization, today announced that Eduard E. Holdener, M.D., formerly Head of Global Pharmaceutical Development at F. Hoffmann-La Roche, Ltd., has been elected to its Board of Directors.
Dr. Holdener was recently appointed to the role of non-executive Chairman of NovImmune. The biotechnology Company develops new therapeutic agents in the field of immune-related disorders and inflammation.
"With 22 years of biopharmaceutical industry experience, which has included managing global operations and overseeing global drug development during the past nine years for a major pharmaceutical company, Dr. Holdener will be an excellent addition to PAREXEL and our Board of Directors," said Josef von Rickenbach, PAREXEL's Chairman and Chief Executive Officer. "Our clients and shareholders will certainly benefit from the extensive expertise Dr. Holdener brings to the Company as we continue to be a premier provider to the biopharmaceutical industry in the development and commercialization of important new therapies worldwide."
In his former role as Global Head of Pharmaceutical Drug Development at
Roche, Dr. Holdener successfully led a worldwide development organization,
which was instrumental in receiving approvals for key oncology, virology,
rheumatology, and anemia drugs in many related indications. He also served
as the Company's Chief Medical Officer. During his career with the Company,
he helped to establish and expand the oncology therapeutic area, and was
presented with the Roche Research and Development Prize in the early 90's.
Dr. Holdener led the Company's development operations in Japan fo
Copyright©2008 PR Newswire.
All rights reserved